Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Delamanid Dose Escalation in MDR-TB
NCT01131351Phase 2Terminated
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization
- Start
- Feb 2010
- Primary completion
- May 2011
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label trial of delamanid in pulmonary tuberculosis (TB) (2 arms), sponsored by Otsuka Pharmaceutical Development & Commercialization. Primary endpoints: Percentage of Participants With Potentially Clinically Significant Abnormalities in Vital Signs up to 40 weeks, Percentage of Participants With Potentially Clinically Significant Abnormalities in Electrocardiogram (ECG) Results up to 40 weeks and 7 more. Started Feb 2010; status: terminated.
02
Drugs
delamanid
03
Conditions
pulmonary tuberculosis (TB)
Beyond the preview
Go deeper on NCT01131351.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01131351.